Where does Viking Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Viking Therapeutics, Inc. ranks #27,782 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Viking Therapeutics, Inc. hold?

Viking Therapeutics, Inc. holds 10 US utility patents granted between 2021 and 2025, spanning 6 technology areas.

What is Viking Therapeutics, Inc.'s Innovation Score?

Viking Therapeutics, Inc. has an Innovation Score of 49.9 out of 100 (top 14% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Viking Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Viking Therapeutics, Inc..

What does claim depth mean for Viking Therapeutics, Inc.'s patents?

Viking Therapeutics, Inc.'s patents average 21.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Viking Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Viking Therapeutics, Inc.

Q: What technology areas does Viking Therapeutics, Inc. focus on?

Viking Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Viking ranks #27,782 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 6 technology areas.

#27,782
of 49,997 US assignees by volume: Top 14%
by Innovation Score (49.9/100): 21.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R27782 · US Corporation #27,782 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 10 grants
MID-PACK #27,782/49,997
PHOTO-FINISH Veyes
CPC-NARROW A61P · 6 areas
INNOV-PAR 49.9/100
CLAIMS-DENSE 21.6 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Veyes LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Viking Therapeutics · this assignee

50
3D Lighting… · lowest

7

What this shows Viking's Innovation Score is 49.9/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Viking's grants concentrate

Viking Therapeutics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 80% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2021. By volume, Viking sits between Veyes LLC and Viridity Energy, Inc..

Viking's three-year grant acceleration

Viking Therapeutics, Inc. shows 6 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Veyes

10
Via Fortuna

10
Victory Industrial

10
Vidrio Plano de M…

10
Virewirx

10
Virgin Instruments

10
Virginia Polytech…

10
Viridity Energy

10
Viking Therapeuti… ◀

10

What this shows Viking holds 10 patents at rank #27,781, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Viking

By rank, the assignees closest to #27,781 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Viking's primary technology class.

Viking's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Viking Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	10.0%
2022	1	10.0%
2023	3	30.0%
2024	2	20.0%
2025partial year	3	30.0%

Which technologies does Viking Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C07K - Peptides 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#27,782

of 49,997 tracked assignees

Innovation Score

49.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Viking Therapeutics, Inc.'s patent record in context - here's where to go next.

Viking Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #27,782 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Viking Therapeutics, Inc. against Veyes LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.